CAI — Caris Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $10.40bn
- $10.06bn
- $412.26m
- 45
- 11
- 66
- 35
Annual income statement for Caris Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 306 | 412 |
| Cost of Revenue | ||
| Gross Profit | 91.3 | 180 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 637 | 669 |
| Operating Profit | -330 | -257 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -341 | -282 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -341 | -282 |
| Net Income Before Extraordinary Items | ||
| Net Income | -341 | -282 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -463 | -378 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.62 | -1.36 |